부산대학교 도서관

Palmoplantar psoriasis is plaque psoriasis involving the palms and soles. Palmoplantar psoriasis is a treatment challenge for dermatologists and it is difficult to treat with topical and systemic therapies. Owing to its location and manifestations, palmoplantar psoriasis is associated with greater pain, functional limitations, and significant impairment of health-related quality of life. Recently a new biologic agent, secukinumab, has been approved for treatment of moderate to severe plaque psoriasis. GESTURE trial is a study of the secukinumab clinical development that evaluates efficacy and safety in this subpopulation of patients. We present a patient with palmar psoriasis refractory to systemic treatments who showed a gradual and complete response to secukinumab sustained at week 30 and without adverse events. Our patient had a significant improvement in his quality of life and work activity.